Flag of the European Union EU Clinical Trials Register Help

Clinical trials for RNA viruses

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    180 result(s) found for: RNA viruses. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2011-004928-35 Sponsor Protocol Number: VX-950HPC3008 Start Date*: 2012-02-29
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Ge...
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005500-14 Sponsor Protocol Number: MZ-ATRACTION/ML 20804 Start Date*: 2007-09-05
    Sponsor Name:Universitätsmedizin der Johannes-Gutenberg Universität Mainz
    Full Title: A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGA...
    Medical condition: chronic HCV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019183 HCV LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004724-35 Sponsor Protocol Number: VX-950HPC3006 Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000150-12 Sponsor Protocol Number: 7009 Start Date*: 2009-09-07
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ...
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019751 Hepatitis C virus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) SE (Completed) DE (Completed) BE (Completed) GB (Prematurely Ended) CZ (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000685-42 Sponsor Protocol Number: 2DR-study Start Date*: 2020-04-30
    Sponsor Name:Ghent University Hospital
    Full Title: Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial.
    Medical condition: human immunodeficiency viruses (HIV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-004999-19 Sponsor Protocol Number: 191001 Start Date*: 2020-06-16
    Sponsor Name:Department of infectious diseases, Hvidovre Hospital
    Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress...
    Medical condition: Human immunodeficiency viruses (HIV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10067326 Antiretroviral therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004812-12 Sponsor Protocol Number: GS-US-337-1612 Start Date*: 2015-05-07
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Subjects with Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and C...
    Medical condition: Acute Genotype 1 or Genotype 4 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10070218 Hepatitis C virus test positive PT
    18.0 10022891 - Investigations 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019843-20 Sponsor Protocol Number: TMC435HPC3002 Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen R&D Ireland
    Full Title: A Prospective 3-Year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study With a TMC435-Containing Regimen for the Treatment of Hepatitis C Virus (HCV) infection
    Medical condition: Hepatitis C Virus (HCV)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000620-26 Sponsor Protocol Number: MK-3682B-034 Start Date*: 2016-11-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic H...
    Medical condition: Chronic Hepatitis C Infected Patient
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10019183 HCV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000672-25 Sponsor Protocol Number: MK-5172-059 Start Date*: 2014-12-31
    Sponsor Name:Merck Sharp & Dohme Copr., a subsidary of Merck & Co.
    Full Title: A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis and Chi...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) EE (Completed) PL (Completed) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000149-72 Sponsor Protocol Number: 7009 Start Date*: 2008-08-20
    Sponsor Name:Merck Sharp & Dohme de España, S.A.
    Full Title: A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Pati...
    Medical condition: Chronic hepatitis C infection Infección crónica por Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019751 Hepatitis C virus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) AT (Completed) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-011464-11 Sponsor Protocol Number: VX08-950-112 Start Date*: 2009-10-20
    Sponsor Name:Vertex Pharamceuticals, Inc.
    Full Title: EXTEND: A 3-Year, Virology, Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies
    Medical condition: Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003858-25 Sponsor Protocol Number: MK-5172-052 Start Date*: 2014-03-10
    Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney D...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10019183 HCV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) SE (Completed) EE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002296-17 Sponsor Protocol Number: GS-US-337-0121 Start Date*: 2013-09-02
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks with Ribavirin or for ...
    Medical condition: Chronic Genotype 1 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-009214-40 Sponsor Protocol Number: A8121014 Start Date*: 2009-07-08
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INF...
    Medical condition: Treatment of chronic HCV genotype 1 infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) ES (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003187-37 Sponsor Protocol Number: MK-5172-083 Start Date*: 2016-01-25
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) with and without Ribavirin (RBV)...
    Medical condition: Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003978-27 Sponsor Protocol Number: GS-US-337-1119 Start Date*: 2014-02-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Ge...
    Medical condition: Chronic Genotype 4 and Genotype 5 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022092-65 Sponsor Protocol Number: ACH625-003 Start Date*: 2011-10-13
    Sponsor Name:Achillion Pharmaceuticals, Inc.
    Full Title: A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in comb...
    Medical condition: Hepatitis C Virus Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10019751 Hepatitis C virus LLT
    14.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000523-40 Sponsor Protocol Number: HAI115879 Start Date*: 2012-09-11
    Sponsor Name:GlaxoSmithKline Research and Devlopment Ltd
    Full Title: A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of G...
    Medical condition: Hepatitis C virus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-010590-20 Sponsor Protocol Number: TMC435-TiDP16-C206 Start Date*: 2009-10-21
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including PegIFNα-2a ...
    Medical condition: Hepatitis C Virus (HCV)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) AT (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:04:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA